Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $139.5 million.

  • Axsome Therapeutics' Accumulated Expenses rose 102.82% to $139.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.5 million, marking a year-over-year increase of 102.82%. This contributed to the annual value of $74.0 million for FY2024, which is 58.31% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Accumulated Expenses stood at $139.5 million, which was up 18.03% from $118.2 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Accumulated Expenses peaked at $139.5 million during Q3 2025, and registered a low of $2.7 million during Q1 2022.
  • In the last 3 years, Axsome Therapeutics' Accumulated Expenses had a median value of $63.5 million in 2024 and averaged $69.5 million.
  • Data for Axsome Therapeutics' Accumulated Expenses shows a peak YoY soared of 1,015.79% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Accumulated Expenses stood at $26.5 million in 2022, then spiked by 75.98% to $46.7 million in 2023, then spiked by 58.31% to $74.0 million in 2024, then spiked by 102.82% to $139.5 million in 2025.
  • Its Accumulated Expenses was $139.5 million in Q3 2025, compared to $118.2 million in Q2 2025 and $95.8 million in Q1 2025.